Outpace Bio: Funding, Investors & Team (Oct 2026)
Outpace Bio is a biotech company that specializes in developing advanced cell therapies designed to enhance effectiveness and safety. Their platform integrates personalized biological functions with cellular control methods to trigger the appropriate response when and where needed. By working in partnership with Lyell Immunopharma, they are working towards creating immune cell therapies that can potentially treat a variety of illnesses, offering personalized solutions for patients with conditions such as cancer, autoimmune diseases, infectious diseases, and more. This collaboration aims to provide healthcare providers with the ability to effectively treat a diverse range of illnesses based on individual patient needs.
Outpace Bio has raised $169M across 2 funding rounds on record, the most recent a Series B of $144M announced in Aug 2024.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Outpace Bio Company Profile and Key Stats
Latest funding round on record: Aug 2024.
Outpace Bio Funding Rounds
Outpace Bio raised $25.0M in a Series A announced in Mar 2023.
1.4 years later, a Series B of $144M was announced in Aug 2024.
Outpace Bio Founders and Leadership Team
No contact details are on record for this team yet.
Outpace Bio Funding Compared to Other Biotechnology Startups
Outpace Bio's latest round of $144M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Outpace Bio in Biotechnology and Seattle
Companies Similar to Outpace Bio
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Datavant is a developer of a healthcare data platform dedicated to assisting in protecting, matching, and…
Outpace Bio Funding FAQs
What does Outpace Bio do?
Outpace Bio is a biotech company that specializes in developing advanced cell therapies designed to enhance effectiveness and safety. Their platform integrates personalized biological functions with cellular control methods to trigger the appropriate response when and where needed. By working in partnership with Lyell Immunopharma, they are working towards creating immune cell therapies that can potentially treat a variety of illnesses, offering personalized solutions for patients with conditions such as cancer, autoimmune diseases, infectious diseases, and more. This collaboration aims to provide healthcare providers with the ability to effectively treat a diverse range of illnesses based on individual patient needs.
How much funding has Outpace Bio raised?
Outpace Bio has raised $169M across 2 rounds on record. The most recent is a Series B of $144M announced in Aug 2024.
When did Outpace Bio last raise funding?
Outpace Bio's most recent funding round on record is a Series B of $144M, announced in Aug 2024.
Who founded Outpace Bio?
FundedIQ lists Marc Lajoie (Founder) at Outpace Bio.
Where is Outpace Bio headquartered?
Outpace Bio is based in Seattle, Washington, United States.
How many employees does Outpace Bio have?
Outpace Bio is in the 51-100 employee band.
How does Outpace Bio's funding compare to other Biotechnology startups?
Outpace Bio's latest round of $144M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Outpace Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Outpace Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.